Publications
Search our bibliography using the filters on the right-hand side.
Displaying 351 through 400 of 599 publications.
Skip to main content
Wolowacz SE, Pearson IV, Roskell NS, Shannon PR, Chubb B, Gundgaard J. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Presented at the Mount Hood Six Challenge; June 7, 2012.
Mauskopf J, Talbird S, Standaert B. Categorization of methods used in cost-effectiveness analyses of vaccination programs based on outcomes from dynamic transmission models. Expert Rev Pharmacoecon Outcomes Res. 2012 Jun 1;12(3):357-71.
Mladsi DM, Graham JB, Ronquest NA. Trade-off analysis: an extension of threshold pricing analysis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A169.
Mladsi D, Herring WL, Earnshaw S. Cost-effectiveness analysis in personalized medicine: general hypotheses and corresponding decision tree structures for screening, diagnostic, predictive, prognostic, surveillance, and monitoring tests. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A168-9.
Karve SJ, Price G, Davis KL, Pohl G, Smith EN. Comparison of treatment patterns, health care utilization, and direct costs in elderly patients with distant-stage small cell lung cancer (SCLC) versus non-small cell lung cancer (NSCLC) using the SEER-medicare database. Poster presented at the Annual Meeting of the American Society of Clinical Oncology; June 2012.
Thompson JR, Talbird SE, Mauskopf JA, Brogan AJ, Standaert B. Translating outcomes from a dynamic transmission model for vaccination to cost-effectiveness estimates: the impact of different analytic approaches on the results. Presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A10.
Brogan AJ, Talbird SE, Thompson J, Miller JD, George S, Hvidsten K. Cost-effectiveness of first-line versus second-line telaprevir combination treatment in the management of chronic hepatitis C virus infection for treatment-naïve patients with IL28B genotype CC. Presented at the 2012 Digestive Disease Week; May 2012.
Farkouh RA, Wilson MR, Tarrants ML, Castelli-Haley J, Armand C. Cost-effectiveness of rasagiline compared with first-line early parkinson disease therapies. Am J Manag Care. 2012 May 1;4(3):99-107.
Mladsi D, Curtis S, Bell MJ, Ito T, Wilson M, Aboud M. Resource utilisation and cost of managing adverse events (AEs) associated with highly active antiretroviral therapy (HAART) in patients with HIV-1. Poster presented at the 18th Annual Conference of the British HIV Association; April 1, 2012. Birmingham, UK. [abstract] HIV Med. 2012 Apr 18; 13(SI):17-8.
Cohen C, Davis KL, Meyers JL. Effect of daily antiretroviral pill burden on hospitalizations in United States medicaid enrollees with HIV: an analysis of hospital characteristics and costs. Poster presented at the 24th Annual Meeting of the Academy of Managed Care Pharmacy; April 2012.
Davis AE, Mehrotra S, Friedewald J. Improving utilization and outcomes of high kidney donor profile index kidney transplants. Poster presented at the 2012 American Transplant Congress; April 2012.
Poulos C, Riewpaiboon A, Stewart JF, Clemens J, Guh S, Agtini M, Sur D, Islam Z, Lucas M, Whittington D. Costs of illness due to endemic cholera. Epidemiol Infect. 2012 Mar 1;140(03):500-9.
Auzinger G, Playford G, Graham CN, Narula H, Charbonneau C, Weinstein D. Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia. Poster presented at the International Symposium of Intensive Care and Emergency Medicine; March 2012.
Brogan AJ, Deniz B, Miller JD, Mladsi DM, Herring WL, Thompson JR. Cost-effectiveness assessment of telaprevir combination therapy compared with pegylated interferon and ribavirin alone in the management of chronic hepatitis C virus infection in Canada. Poster presented at the 2012 Canadian Digestive Diseases Week and the Annual Winter Meeting of the Canadian Association for the Study of the Liver; February 24, 2012. Montreal, Canada. [abstract] Can J Gastroenterol. 2012 Feb; 26(Suppl(SA)).
Kauf TL, Davis KL, Earnshaw SR, Davis EA. Spillover adherence effects of fixed-dose combination HIV therapy. Patient Prefer Adherence. 2012 Feb 1;6:155-64.
Zimovetz EA, Wolowacz SE, Classi PM, Birt J. Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic review. Cost Eff Resour Alloc. 2012 Feb 1;10(1):1.
Mauskopf JA, Graham JB, Bae JP, Ramaswamy K, Zagar AJ, Magnuson EA, Cohen DJ, Meadows ES. Cost-effectiveness of prasugrel in a US managed care population. J Med Econ. 2012 Jan 1;15(1):166-74.
Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia. Value Health. 2012 Jan 1;15(1):55-64.
Mauskopf J, Brogan AJ, Talbird SE, Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS. 2012 Jan 1;26(3):355-64.
Yen L, Davis KL, Hodgkins P, Loftus EVJr, Erder MH. Direct medical costs of diverticulitis in a US managed care population. Am J Manag Care. 2012;4(5):e118-29.
Alwin J, Brodtkorb T. Could the choice of patient versus proxy ratings for assessing quality of life in dementia affect resource allocation in health care? Farmeconomia e percorsi terapeutici / in collaborazione con sifeit--società italiana per studi di economia ed etica sul farmaco e sugli interventi terapeutici. 2012;13(1):25-31.
Sansgiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. J Med Econ. 2012;15(2):219-24. doi: 10.3111/13696998.2011.638954
Herring WL, Herrmann JW. A stochastic dynamic program for the single-day surgery scheduling problem. IIE Trans Healthc Syst Eng. 2011 Dec 1;1(4):213-25.
Stull DE, Houghton K. Examining variability in depression among pre-retirees: innovative analytic methods applied to observational data. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A301.
Stull DE, Wiklund I, Gale R, Capkun-Niggli G, Houghton K, Jones P. Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. Contemp Clin Trials. 2011 Nov 1;32(6):818-28.
Antela A, Llibre JM, Lopez Bernaldo De Quiros JC, Portilla J, Gallois A, Campbell A, Penafiel J, Brogan AJ, Talbird SE. HIV Treatment Cost-Effectiveness Study Group. An economic model to assess the cost-effectiveness of early treatment initiation for people with HIV infection in Spain. Poster presented at the Third National GESIDA Congress; November 2011. Seville, Spain.
Spinner DS, Mladsi D, Walter J, Ziemiecki R, Stafford-Smith M, Taekman J, Faulkner E. Clinical trial learning curves may impact both clinical and economic outcomes and influence health technology assessment and reimbursement decision making. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. Madrid, Spain. [abstract] Value Health. 2011 Nov; 14(7):A356.
Davis AE, Ladner D, Friedewald J, Mehrotra S. Ameliorating geographic disparities in kidney transplantation rates via optimization approaches. Poster presented at the Annual Meeting of the Institute for Operations Research and Management Science; November 2011. Previously presented at the American Transplant Congress.
Davis AE, Ladner D, Friedewald J, Mehrotra S. Ameliorating geographic disparities in kidney transplantation rates via optimization approaches. Poster presented at the American Society of Nephrologists; November 2011. Previously presented at the American Transplant Congress.
Hicks KA, Karve S, Vlahiotis A, Frazee S, Tian Y, Earnshaw SR. Estimation of increases in direct medical expenditures associated with medication nonadherence and potential savings from increased adherence. Poster presented at the 2011 ISPOR 14th Annual European Congress; November 9, 2011. [abstract] Value Health. 2011 Nov; 14(7):A343-4.
Cohen C, Davis KL, Meyers JL. Effect of daily antiretroviral pill burden on health care utilization and costs in United States Medicaid enrollees with HIV. Poster presented at the 13th European AIDS Conference; October 2011.
Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson JR. Projections using decision-analytic modeling of long-term clinical value of telaprevir for the treatment of HCV patients who had failed prior peginterferon/ribavirin treatment. Poster presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Conference; November 2011. San Francisco, CA. [abstract] Hepatology. 2011 Oct 1; 54(Suppl. 1):802A-3A.
Deniz B, Brogan AJ, Miller JD, Talbird SE, Thompson J. Cost-effectiveness assessment of telaprevir combination treatment compared to pegylated-interferon + ribavirin alone in the management of chronic hepatitis C in patients who failed a prior pegylated-interferon + ribavirin treatment. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 2011.
Loftus EV, Hodgkins P, Davis KL, Yen L. Economic burden of diverticulitis complications in a Unites States managed care population. Poster presented at the Annual Scientific Meeting of the American College of Gastroenterology; October 2011.
Chevrou-Severac H, Ochoa JB, Mauskopf JA, Candrilli SD, Graham JB, Drawert S, Greenberg N. Immunonutrition for gastrointestinal cancer patients: an effective and cost-savings intervention. Poster presented at the 24th Annual Meeting of the European Society of Intensive Care Medicine; October 2011. Previously presented at the 33rd Congress of the European Society for Clinical Nutrition and Metabolism.
Chevrou-Severac H, Mauskopf JA, Candrilli SD, Ochoa JB. Immunonutrition for gastrointestinal cancer patients: an effective and cost-savings intervention. Poster presented at the 33rd Congress of the European Society for Clinical Nutrition and Metabolism; September 2011. Gothenburg, Sweden.
Rubino A, Wallander MA, Callreus T, Saddier P, Ritchey ME, Perez-Gutthann S. Drug utilization studies and risk management plans: a missing link. Poster presented at the 27th International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2011. Chicago, IL. [abstract] Pharmacoepidemiol Drug Saf. 2011 Aug 1; 20(Suppl. 1):S269.
Hauber AB, Fleischmann J, Lothgren M, Wilson M, Lam A, Dubois D, Sabatowski R. Economic evaluation of OROS hydromorphone for chronic pain: a Pan-European perspective. J Opioid Manag. 2011 Jul 1;7(4):287-96.
McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011 Jul 1;22(7):2083-98.
Brogan AJ, Talbird SE, Cohen C. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. Value Health. 2011 Jul 1;14(5):657-554.
Aragãgo F, Vera J, Vaz Pinto I, Talbird SE, Brogan AJ. Economic evaluation of early antiretroviral treatment for HIV-1 infected individuals in Portugal. Poster presented at the 6th Annual Conference of the International AIDS Society; July 2011.
Davis AE, Ladner D, Friedewald J. Ameliorating geographic disparities in kidney transplantation rates via optimization approaches. Poster presented at the Institute for Operations Research and Management Science (INFORMS) Healthcare Conference; June 2011. Previously presented at the American Transplant Congress.
Davis AE, Ladner D, Friedewald J. Analysis of kidney transplant center locations in the United States. Poster presented at the Institute for Operations Research and Management Science (INFORMS) Healthcare Conference; June 2011. Previously presented at the American Transplant Congress.
Davis AE, Ladner D, Friedewald J. Ameliorating geographic disparities in kidney transplantation rates via optimization approaches. Poster presented at the American Transplant Congress; June 2011.
Earnshaw SR, Chirila C, McDade CL, Black L, Andriole GL. Cost-effectiveness of dutasteride as a chemoprevention in prostate cancer: rEDUCE within-trial analysis. Presented at the 2011 ISPOR 16th Annual International Meeting; May 2011.
Mauskopf J, Chirila C, Masaquel CJ, Boye KS, Bowman L, Birt J, Grainger DB. The relationship between financial impact and the likelihood of drug reimbursement in the Australian health care system. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 26, 2011. [abstract] Value Health. 2011 May; 14(3):A22-3.
Karve SJ, Panish J, Dirani R, Candrilli SD. Annual health care costs for patients with schizophrenia experiencing multiple relapses after initiation of a second-generation oral antipsychotic. Poster presented at the 164th Annual Meeting of the American Psychiatric Association; May 2011.
Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA, Danna RP, Papadopoulos G. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2011 May 1;39(4):e15-20.
Ducournau P, Zhao Z, Barber B, Gao S, Graham CN. Methods for indirect comparison of effectiveness in cost-effectiveness analyses of oncology agents: the proportional hazard assumption matters. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2011. Baltimore, MD.
Hoogeveen EK, Aalten J, Rothman KJ, Roodnat JI, Mallat MJ, Borm G, Weimar W, Hoitsma AJ, de Fijter JW. Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation. 2011 Apr 27;91(8):869-74.